Every few weeks, a patient asks me some version of the same question: "Why would I want a lower dose? Isn't more medication better if I want more results?"

It's a fair question, and the answer gets at something I think is widely misunderstood about how these medications actually work.

More dose is not the same as more benefit

The standard titration schedules for GLP-1 medications were built for the average patient in a clinical trial — and averages, by definition, describe nobody exactly. In practice, I've treated hundreds of patients medically with these drugs, on top of thousands of surgical patients before that, and the range of individual response is enormous. Some patients get significant appetite suppression and metabolic benefit at doses well below what's considered "standard." Others need more. Response isn't linear, and it isn't uniform.

The mistake I see most often — from patients and sometimes from providers — is treating dose escalation as the goal itself. It isn't. The goal is the clinical outcome: appetite regulation, metabolic improvement, weight loss that's sustainable and preserves lean mass. Dose is just a lever to get there, not a finish line.

Who tends to do well on a lower-dose approach

In my experience, three groups in particular tend to benefit from a more conservative, lower-dose strategy rather than the standard escalation schedule:

Patients who respond strongly at low doses. Some people get most of the appetite and metabolic benefit at a fraction of the standard dose. Pushing them higher doesn't add proportional benefit — it mostly adds side effects.

Patients with a history of significant GI side effects. For patients who've struggled with nausea, reflux, or slowed digestion on other medications, a slower, lower-dose approach often achieves the same long-term outcome with a far more tolerable path there.

Patients focused on sustainability over speed. Some patients want the fastest possible results. Others — often the ones I'd bet on long-term — want a pace they can actually live with for years, not months. Lower, steadier dosing tends to support the second group better than aggressive escalation does.

Why this isn't just "start low and go slow"

Every provider will tell you to start low and titrate slowly — that's standard practice, not a special insight. What I mean by a low-dose approach is something more specific, and it's worth being precise about: this is still dosing within the standard, FDA-approved range for these medications. It's not about going below approved starting doses — it's about recognizing when a patient has found their effective dose well before reaching the top of that standard schedule, and having the clinical judgment to stop escalating rather than continuing on to some default target dose that was written for the average patient in a trial.

This requires paying close attention to what's actually happening with a patient — appetite, side effects, metabolic markers, body composition — rather than following a checklist that ends at "highest tolerated dose." A dose that gets a patient 90% of the benefit with a fraction of the side effects is very often the better clinical choice, even if it's a smaller number than what a standard protocol would default to.

What I'd want you to take from this

If you're on a GLP-1 and assuming that reaching the maximum dose is the goal, I'd push back on that assumption. The goal is the outcome you're actually looking for — sustainable results, minimal side effects, preserved muscle, a pace you can maintain. For a meaningful number of patients, that outcome shows up well before the top of the standard schedule.

The right question isn't "how high should I go." It's "what's the lowest dose that gets me the outcome I actually want." Those aren't always the same number, and figuring out which one applies to you is exactly the kind of judgment that should come from an ongoing relationship with your provider, not a fixed schedule applied the same way to everyone.

Curious whether a lower-dose approach might fit your situation? [Reach out / subscribe / etc. — placeholder for your CTA.]